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Oral Presentations S217In order to identify the immune dominant H-Y epitope(s), we de-
veloped a high-throughput H-Y microarray. Five H-Y proteins and
their 95% identical X-chromosome homologs (H-X) were printed
on epoxy glass slides along with fifty 15-19 amino acid overlapping
disparate H-Y peptides. Normal male donors have negligible H-Y
antibodies. H-Y seropositive thresholds were mean result of 31
healthy males + 3 SD. The H-X homologue is scored using its cor-
responding H-Y antigen threshold.
Plasma samples from 32male patients with female donors (F/M)
who developed cGVHD, had sera tested for H-Y specific IgG and
IgM, 6, 12,18 months after HCT. Twenty-two of 32 (69%) had
anti-DBY (aka DDX3Y) antibodies by microarray and ELISA (R2
5 0.85). DBY-2 was recognized by 17/32 (36%) overall and ac-
counted for 77% of DBY responders.
We used this immune dominant peptide to FACS stain DBY-2
specific B cells. DBY-2 biotinylated peptide was used to capture
the antigen specific B cells and was later detected by streptavi-
dine-Qdot along with markers of B cell development. Ten healthy
males had no detectable DBY-2 staining. Peripheral blood mono-
nuclear cells (PBMCs) collected days 90, 180, 270, and 365 post
HCT from 25 F/M patients and stained for DBY-2 in relation
to DBY IgG and IgM in plasma (Table). Seven of 11 (64%) had
DBY-2 specific B cells detected as early as 90-180 days. Further,
3 of 7 (43%) of DBY and DBY-2 IgG seronegative patients tested
persistently DBY-2 B cell positive. Day 90 and 180 detected DBY-
2 B cells showed na€ıve phenotype (IgD+IgM+CD38+CD27-).
In contrast, .30% DBY-2 B cells at 1-year were activated
CD27+. The range of DBY-2 B cells at 1y was 0.3-0.8 % of
CD19+ cells.
This is the first identification of human allogeneic B cells and
surprisingly they develop months before subsequent allo-IgG and
are detected in 40-50% of seronegative F/M. Immune dominant
DBY-2 B cell isolation now enables allogeneic B cell functional
studies.
Table. H-Yantibodies and B cells detected in 32 male patients
with female donors
Protein ELISA Peptide ELISA DBY-2 B cellsF/M HCT
n 5 32 DBY IgG DBX-2 IgG DBY-2 IgM d180 d365DBY IgG
pos n 5 2222/22 (100%) 0/22 6//22 (27%) 7/11 (64%) 7/11 (64%)DBY-2 IgG
pos n 5 1712/17 (71%) 0/17 5/17 (29%) 4/11 (36%) 5/13 (39%)DBY-2 IgG
neg n 5 1510/15 (67%) 1/15 (7%) 1/17 (7%) 3/7 (43%) 4/7 (56%)Healthy Male 0/31 0/31 0/31 0/10 0/10ELISA measurements were performed 1 y after transplant.39
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The majority of patients (pts) with chronic lymphocytic leuke-
mia (CLL) with an indication for allogeneic hematopoietic cell
transplantation (HCT) suffer from refractory disease. Lower tu-
mor load prior to HCT may be associated with better outcome.
Thus, cytoreductive pre-treatment needs to be considered. Alem-
tuzumab has proven activity in refractory disease. On the other
hand, pre-treatment with alemtuzumab has been associated with
inferior outcome after HCT in a retrospective analysis. We pres-ent results from a phase II trial where we systematically investi-
gated treatment with alemtuzumab followed by a washout
period and subsequent reduced intensity conditioning (RIC) prior
to allogeneic HCT.
Methods:All pts were scheduled for onemonth of treatmentwith 30
mg alemtuzumab 3 times weekly. The washout period between the
last dose of alemtuzumab and the day of HCT was increased from
twoweeks to onemonth during the study. Antibody levels weremea-
sured on the day of HCT and T-cell engraftment was monitored.
RIC consisted of fludarabine (150 mg/m2) and busulfan (8 mg/kg).
Cyclosporine (CSA) and methotrexate (MTX) were administered
as GVHD-prophylaxis.
Results: 62 pts with relapsed or refractory CLL and a median age of
56 years were included. Two pts failed to reachHCTdue to progres-
sive disease under therapy. Donors were HLA-identical siblings (N
5 26) orHLA-compatible unrelated donors accepting onemismatch
(N 5 34). No primary or secondary graft failure occurred. Interfer-
ence of persisting antibody levels with T-cell engraftment could be
demonstrated even after a washout period of one month in 4 out of
30 pts (ASH 2009, 114:3351). The cumulative incidence of acute
GVHD grades II to IV at day +100 was 42%, and that of extensive
chronic GVHD at one year was 56%. With a median follow-up of
35 months (16 to 61 months) 3-year overall survival and progres-
sion-free survival were 62% (95% CI, 48% to 76%) and 52%
(95% CI, 38% to 66%). Day +100 non-relapse mortality was 2%.
At 3 years non-relapse mortality and relapse incidence were 24%
(95% CI, 12% to 36%) and 24% (95% CI, 13% to 35%), respec-
tively.
Conclusions:The favorable long-term results of this study argue in
favor of that strategy for patients with refractory disease. However,
unless in vivo T-cell depletion is the goal, a washout period of a min-
imum of one month after the last dose of alemtuzumab should be
kept and T-cell engraftment needs to be monitored.40
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Respiratory syncytial virus (RSV), a single-stranded RNA virus of
the Paramyxoviridae family, is one of the most common causes of
respiratory infections during childhood. Although most children
are infected with this virus by 2 years of age resulting in the produc-
tion of neutralizing antibodies, life-long immunity is not induced.
Nosocomial spread is common, even among immunocompetent in-
dividuals. Following allogeneic HSCT, progression from upper re-
spiratory tract to lower tract disease occurs in 40-60% of cases and
is generally fatal if left untreated. In a prior study at our institution,
16 of 21 patients infected during the first post HCT month devel-
oped pneumonia. In an effort to prevent RSV infection in unrelated
and HLA-mismatched transplant recipients, intravenous palivizu-
mab (15 mg/kg infused at 20-40 mg/minute) was administered to
60 of 142 patients \21 years of age transplanted between 2005
through 2009. Patients who received prophylactic palivizumab
were younger, more likely to have been transplanted after 2007,
to be the recipient of an HLA-mismatched donor transplant,
and/or to have GVHD. Patients received a median of 3 doses of
palivizumab at 4-6 week intervals during the RSV season. All doses
were well tolerated and resulted in an RSV neutralizing antibody
titer of 1:640-.1:1280. An RSV infection developed in 6 of 60 pa-
tients who received prophylaxis and 17 of 82 who did not, (p 5
0.04). Of the 17 patients who developed RSV in the absence of pro-
phylaxis, 9 were treated with palivizumab, and none developed
pneumonia. This retrospective study demonstrates that IV palivizu-
mab is safe and suggests it can prevent infection. Future studies
evaluating the number of doses needed to prevent disease, the op-
timum population to target, and the cost effectiveness of this strat-
egy are warranted.
